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Study of EHS type IV collagen lacking Goodpasture's epitope in
glomerulonephritis in rats. The Goodpasture's epitope has been mapped
to the 03 non-collagenous chain (NC1) of type (IV) collagen [a3col(IV)].
We have developed a model of experimental autoimmune glomerulone-
phritis (EAG) in rats immunized once with collagenase solubilized GBM
(c5GBM). Engelbreth-Holm-Swarm (EHS) tumor contains abundant
col(IV) with little or no a3col(IV). To test the hypothesis that antigens
related to Goodpasture epitope are required to produce EAG in our
model, we immunized rats once with 40 g csEHS. Positive controls
immunized with csGBM developed typical EAG with GBM bound
antibody, proteinuria, and glomerulonephritis. EHS rats developed circu-
lating and bound antibody to mesangium and tubular basement membrane
with minimal GBM deposits, but did not develop proteinuria or glomer-
ulonephritis. Although circulating antibody in EHS rats bound to csGBM
by ELISA, there was no binding in ELISA to M2 antigen containing the
Goodpasture epitope while EAG rat's serum did bind. By Western blot
with antisera to Goodpasture epitope, EHS antigen was less complex than
GBM in the monomer/dimer regions and appeared to lack NC1 corre-
sponding to a3col(IV). Blotting with sera from EHS rats demonstrated
reactivity to various components of GBM but not to a3col(IV). EAG sera
and renal eluates bound to a3col(IV). EAG rats evidenced cell mediated
immunity while EHS rats did not (stimulation index EHS 1.1, EAG rats
8.0). These studies show that the development of antibody to col(IV) in a
setting conducive to EAG does not cause EAG in the absence of
a3col(IV) NC1, that the antibody response in EHS rats was not associated
with a cellular response to the antigen and that an epitope on the same
NC1 o3col(IV) which contains the Goodpasture epitope appears neces-
sary to induce EAG in this model. These studies further implicate the
a3col(IV) as a pathogenetic factor in the development of Goodpasture
syndrome in humans as well as a marker of disease.
Glomerulonephritis in humans associated with antibodies to
the glomerular basement membrane (GBM) occurs in two general
forms, the first without pulmonary involvement, a variant of
rapidly progressive glomerulonephritis (RPGN) usually associ-
ated with crescents, and the second with deposition of antibody on
lung basement membrane and pulmonary hemorrhage, classic
Goodpasture syndrome [1, 2]. These diseases appear to result
from loss of innate tolerance consequent to various etiologic
factors including infections and toxins, with a major influence of
genetic predisposition [3, 4]. The syndrome has long been consid-
ered to result from deposition of preformed circulating antibodies
with the responsible antigen uniquely concentrated within the eye,
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cochleae of the ear, lung and renal basement membranes [5, 6].
The serum of patients with Goodpasture syndrome contains
antibody activity against the non-collagenous 1 (NC1) domain of
type IV collagen [col(IV)1 including type IV collagen derived
from Engelbreth-Holm-Swarm (EHS) murine tumor. Recently
the putative Goodpasture epitope has been localized to the NC1
domain of the novel GBM a3col(IV) chain by peptide mapping
[7—91. However, it has not been demonstrated that antibodies
directed to this chain are sufficient for induction of disease nor
have the roles of ancillary factors including other antibody species
been elaborated. Elucidation of these factors requires an appro-
priate animal model since studies of this type obviously cannot be
accomplished in humans.
We have developed a model of experimental autoimmune
glomerulonephritis (EAG) in rats immunized once with collage-
nase solubilized (cs) GBM [10]. Circulating and bound antibody
appear by two to three weeks with proteinuria, proliferative
glomerulonephritis and progression to glomerular and interstitial
scarring. The model appears uniquely similar to anti-GBM dis-
ease in man morphologically, clinically, and immunologically.
Genetic predisposition, cell mediated immunity, and the condi-
tions of immunization appear pivotal in the production of this
model. We hypothesized that the same Goodpasture epitope
defined with peptide mapping was responsible for production of
EAG in our model because of the close similarity to human
anti-GBM disease. To investigate this hypothesis further, it was
necessary to either immunize animals with purified a3col(IV) or
to utilize preparations lacking a3col(IV). Isolation of purified
a3col (IV) involves multiple chromatographic and other purifica-
tion steps, and is an extremely complicated, laborious procedure
which yields only one microgram of purified protein from one
bovine or human kidney [11, 12]. Therefore, we sought to
approach our hypothesis by utilization of collagen lacking the
Goodpasture epitope.
The EHS murine tumor produces abundant col(IV) consisting
mainly of a and a2 chains with minimal or no 03, 04 or 05 [13, 14].
Other investigators have described variable production of renal
lesions utilizing EHS but none have reported associated severe
proteinuria or proliferative nephritis, and none employed the
protocol or strain of animals which we use to produce EAG.
Indeed, production of EAG by this protocol is strain specific [15]
(personal observation). Therefore, to test the hypothesis that the
antigens related to Goodpasture epitope were necessary to pro-
duce EAG in our model, we immunized rats with csEHS or
csGBM. Inability to produce EAG with EHS would implicate the
404
Bolton et al: EHS experimental glomerulonephritis 405
Goodpasture epitope in the induction of glomerulonephritis in
this model, and extend the similarities between the model and the
human disease.
Methods
Animals
Male Wystar-Kyoto (WKY) rats weighing 200 g were obtained
from Charles River and Harlan Sprague-Dawley Laboratories.
Animals were maintained in the Vivarium on a standard diet.
Preparation of basement membranes
Bovine kidneys from a local abattoir and human kidneys
obtained at necropsy were frozen at —70°C until use. They were
thawed at 4°C in phosphate buffered saline (PBS) and the
glomeruli isolated as previously described [10, 16]. Preparations
were 95% pure glomeruli. GBM was obtained from glomeruli by
sonication and digested with type VII collagenase (Sigma Chem-
ical Corp., St. Louis, MO, USA) [10, 16]. In some studies, isolated
hexamers of bovine GBM were used. For these studies, GBM was
solubilized, dialyzed against 2 M urea 0.05 M Tri-HCI, pH 7.5 and
chromatographed on a DE 52 (Whatman) ion exchange column
(2.5 X 40 cm) equilibrated in the same buffer, as described by
Wieslander et a! [17]. The eluate containing the globular domain
which does not bind to the column under these conditions was
dialyzed against 2 M urea, 0.05 M Tri-HC1, pH 9.0 and then
chromatographed on a column (2.5 X 20 cm) of DE 52 equili-
brated in the pH 9.0 buffer. Hexamer bound to the column and
was eluted with a salt gradient from 0 to 0.2 M in NaC1. The peak
containing the globular region was concentrated by ultrafiltration
(Amicon) and used in gel studies. For preparation of basement
membranes from EHS antigen, the EHS tumor was grown in
mice. Two different methods were used to prepare the EHS. The
first method is essentially the same as that used for preparation of
GBM described above. Tumor was homogenized in 1.0 M NaCI
after which the homogenate was centrifuged at 121 X g for 15
minutes. It was washed in 1.0 M NaCI followed by three washes in
distilled water. After centrification at 4,340 >< g the material was
lyophilized. We used a second method as well because it is the
process used by others to characterize EHS col(IV) and to
immunize animals [13, 141. In this method, homogenized tumor
was washed in 3.4 M NaCI in PBS and then extracted twice for 24
hours using 0.5 M NaC1 in PBS pH 7.0. The matrix was further
extracted for three days at 4°C in 0.5 M acetic acid and the residual
tumor matrix lyophilized. These preparations are designated
saline suspended (SS) EHS and acetic acid (AA) extracted EHS.
Both preparations were collagenase digested as for GBM prior to
utilization in immunization.
Immunizations
All animals received 0.5 ml of 1010 Bordetella pertussis organ-
isms/ml intraperitoneally once (Difco Laboratories, Detroit, MI,
USA) [10]. Forty micrograms of csBGBM, csEHS-AA or
csEHS-SS were suspended in acid and complete Freund's adju-
vant (CFA) and administered as a single injection in one foot pad.
Eight rats received EHS-AA, eight received EHS-SS and six
animals were immunized as positive controls with csBGBM.
Normal animals or normal animals that received CFA served as
naive controls.
Histopathology
Light microscopy. Tissue fixed in 10% buffered formalin, em-
bedded in paraffin, and serially sectioned at 3 m in thickness
were stained with hematoxylin eosin (H&E) and assessed without
knowledge of type of immunization schedule [10, 16].
Immunofluorescence microscopy. Immunofluorescence studies
of kidney tissue were done using commercial monospecific fluo-
rescein labeled antisera directed to rat IgG, C3 and fibrinogen.
The intensity of deposits was graded from 0 to 4+ as described
previously and a semiquantitative score obtained [16, 18].
Biochemical studies. Animals were placed in metabolic cages
and urine collected for 24 hours to determine the total urinary
protein (TUP). The TUP assay was performed using 3% sulfosal-
icylic acid with bovine serum albumin as a standard [16].
Preparation of mononuclear cells and blast transformation stud-
ies. Spleens and lymph nodes were utilized as a source of
mononuclear cells prepared by separation on Lymphoprep (Nyg-
aard Company, Norway) [16, 18]. Cultures were performed in
quadruplicate with 7.5 X 1O4 cells per well and 100 xWm1 of
antigen. Con A stimulated positive controls were cultured at 4
.g/ml. Data are expressed as a stimulation index (SI), the ratio of
test-to-medium counts.
Antibody assays. Sera from immunized animals were examined
by different techniques to characterize the formation of circulat-
ing anti-basement membrane antibodies. The first of these was by
indirect immunofluorescence utilizing rat and human kidney
sections with rats sera diluted 1:20 to 1:40 and fluorescein labeled
anti-rat IgG as the second antibody [16]. Bound antibodies were
visualized using 2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic
acid (ABTS) and reading absorbance at 405 nm. In the second
method, ELISA were performed using Immunlon H plates (Dy-
natech Laboratories, Inc., Alexandria, VA, USA) coated with
digested bovine or human GBM 10 j.g/ml, or with EHS-AA or
EHS-SS at the same concentration [161. Selected sera were also
examined with a commercial kit, Scimedx (Denville, NJ, USA) in
which the antigen used is the M2 subunit containing Goodpasture
antigen chromatographically purified from the NC1 domain of
col(IV) isolated from bovine GBM. Controls included buffer
alone, blanks without second antibody and omission of antigen.
Known positive and negative sera were run. Kidneys from ne-
phritic rats were acid eluted, the eluate neutralized and used for
immunoblotting [16].
SDS-PAGE and immunoblotting
SDS-PAGE was performed using gels consisting of 10% poly-
acrylamide or gradient gels from 5 to 20% as described by
Laemmli [19]. Reduced and unreduced samples were applied and
electrophoresed by standard methodologies. Proteins were dee-
trophoretically transferred to nitrocellulose or PVDF paper. After
transfer of protein, membranes were blocked with 1% goat serum
or 5% bovine serum albumin (BSA) for two hours at room
temperature or overnight at 4°C and then various sera samples
diluted 1:100 in 0.05 M PBS were overlaid for one hour. Bound
IgG was demonstrated using horseradish peroxidase conjugated
goat anti-rat IgG at a dilution of 1:100. In some blotting studies,
chemiluminescence was utilized following the protocols supplied
by the manufacturer (Amersham), To facilitate comparison of
different blotting sera, membranes were sequentially stripped and
then blotted with sera of interest. Blots were always performed
ELISA
Fig. 1. Levels of anti-GBM antibodies in experimental rats. Sera were
examined by ELISA using plates coated with csGBM or bovine M2. Both
EHS-SS and EHS-AA immunized rats developed antibody to csGBM
containing a mixture of components of col(IV) albeit somewhat less than
rats immunized with GBM. On the other hand, only rats immunized with
GBM developed a response to chromatographically purified M2 while
none of the EHS rats developed antibody to M2. < 0.05 vs. EAG.
Symbols are: (D) EAG positive control; (E.) EHS-SS; () EHS-AA; ()
EHS-AA/SS; (U) BAG positive control.
with normal sera as well. Different quantities of antigen were
evaluated to obtain resolution of bands in the monomer and
dimer regions. For both silver and immunoblots, we used 8 .tg
bovine GBM, 1 g bovine hexamer, and 30 g EHS-AA or -SS
antigen. Two ig of a glutathione S-transferase-a3col(IV) fusion
protein reactive to Goodpasture's sera (manuscript in prepara-
tion) were used per lane for those studies.
Statistical Analysis
Data are presented as mean and SEM. Where appropriate, data
are analyzed by the Student's t-test.
Results
All rats immunized with ERS or GBM developed circulating
antibodies to bovine GBM antigen by ELISA (Fig. 1). EHS-AA
rats developed somewhat lower titer circulating antibodies while
EHS-SS animals developed higher titers but less than EAG
postive controls. None of the EHS immunized animals developed
antibody to a3col(IV) (Scimedx) while EAG positive controls did
demonstrate antibody in the assay. EHS-SS immunized animals
developed low antibody levels against EHS-AA by ELISA (0.40
0.16) and a standard response to EHS-SS (1.26 0.02). Animals
immunized with EHS-AA did not develop any antibody against
EHS-SS or EHS-AA (0.13 0.01, 0.12 0.01) by ELISA.
There was slight binding against TBM and mesangial areas by
indirect immunofluorescence utilizing EHS sera applied to saline
perfused normal rat kidney. There was no staining of the GBM.
Silver stains of the GBM, hexamer, and EHS antigens revealed
simplified banding in the monomer and dimer regions of EHS
compared to GBM (Fig. 2). EHS preparations contained multiple
smaller protein components relative to GBM and hexamer.
Western blot of the immunogens of EHS and GBM (Fig. 3A)
1 2 3 4
Fig. 2. SDS-PAGE gel of bovine GBM, lane 1; bovine hexamer, lane 2;
EHS-AA, lane 3; and EHS-SS, lane 4; - silver Stain. Position of molecular
weight markers are indicated.
utilizing a polyclonal anti-serum raised to Goodpasture's epitope,
the last 36 amino acids of a3col(IV) [20], revealed monomer
bands of protein for EHS in the 24 to 26 kD region with dimers at
approximately 40 to 45 kD. Equal amounts of loaded protein for
EHS-SS and EHS-AA demonstrated that more of the loaded
protein was immunoreactive with anti-36mer in the EHS-SS than
EHS-AA preparations. An extra band is clearly evident in GBM
and hexamer dimers not seen in EHS. In our hands, rat antisera
raised against 36mer peptide derived from the human sequence
for a3col(IV) carboxy terminus react slightly with other chains of
the NC1 hexamer as might be expected from homology analysis
and consistent with the blot results in Figure 3. Only peptide
column-purified anti-36mer antibodies are reported to show a
single band [9]. Blots using EAG sera (Fig. 3B) demonstrated
reactivity with multiple components of GBM as well as with EHS
antigens. Once again, an extra protein band in the region corre-
sponding to the novel a3 chain is observed in GBM but not EHS
preparations. EHS-SS sera did not detect proteins in GBM,
EHS-SS or EHS-AA by Western blotting. EHS-AA sera (Fig. 3C)
demonstrated multiple high molecular weight bands in AA, SS,
and GBM preparations, but showed minimal antibody reactivity in
the monomer/dimer regions of GBM and hexamer, and then only
a simplified pattern in the dimer region. Finally, Western blot
analysis of sera on a glutathione S-transferase-a3col(IV) fusion
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1 2 3 4
Fig. 3. Western blots of bovine GBM, 8 jig, lane 1; bovine hexamer, 1 p lane 2; EHS-AA, 30 ji lane3; and EHS-SS, 30 jig lane 4, were overlaid with
antibody to 36mer in A, sernm from a rat with EAG, B, and sernm obtained from an EHS-AA immunized rat, panel C. The same nitrocellulose membrane
was stripped and reblotted with each of the various anti-sera. The region of monomers (M) and dimers (D) are indicated by the arrow heads. Results
are described in the text. Immunoblotting of the same membrane with normal rat serum revealed no discernable bands.
protein reactive with Goodpasture's sera was positive with anti-
36mer, EAG serum, and eluate from nephritic kidneys of GBM
immunized rats, but negative with EHS serum (Fig. 4).
Deposits of rat IgG were present in kidney tissue in all
immunized animals but in a pattern different from the character-
istic intense linear GBM deposits observed with EAG animals
[10]. Rats immunized with EHS-AA had granular and linear
mesangial deposits of IgG and low intensity linear staining of the
tubular basement membrane (TBM) and vascular structures (Fig.
5). Minimal deposits along the GBM were observed in EHS
animals. EHS-SS immunized animals similarly had minimal stain-
ing of the GBM, but again had linear and granular deposits of IgG
in the mesangium and linear deposits of IgG along the TBM and
vascular structures. The average semiquantitative intensity of IgG
deposits determined in blind for the EHS-SS rats were respec-
tively 0.12 0.06 for GBM, 1.84 0.21 for TBM, 1.44 0.14 for
mesangium. For EHS-AA rats, the intensity of deposits were 0.37
0.18 for GBM, 0.84 0.30 for TBM, and 1.25 0.22 for
mesangium. No fibrin deposits were observed in rats immunized
with EHS as opposed to characteristic global and segmental
deposits of fibrin in EAG animals. No abnormal complement
deposits were observed in any of the animals. Immunofluores-
cence analysis of lung tissue did not reveal any fixation of rat IgG
to alveolar basement membranes in any of the immunized rats.
By light microscopy, no histologic abnormalities were present
in any of the animals immunized with EHS antigen, either in
glomeruli, tubules, or in the interstitium. EAG postive controls
had characteristic diffuse proliferative glomerulonephritis.
Control EAG rats predictably developed proteinuria beginning
by week 3 after immunization (Fig. 6) which increased with time.
No abnormal proteinuria was detected in any of the EHS rats up
to the time of sacrifice after the seventh week collection for
proteinuria.
Mononuclear cells obtained from EHS-AA and EHS-SS rats
did not respond to either csGBM or to EHS antigens (Fig. 7),
while EAG rats had a characteristic blast transformation in
response to GBM antigen.
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Fig. 4. Western blot of glutathione S-transferase-acol(JV) ftsion protein, 2
jig, blotted with normal rat serum, lane 1; anti-serum to 36mer, lane 2; serum
from a rat with EAG, lane 3; eluate obtained from kidneys of glomerulone-
phritic rats, lane 4; EHS serum, lane 5; and as a positive control rabbit
antiserum to glutathione S-transferase (GST), lane 6. The broad bands in
the low molecular weight region are GST degradation reactions.
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Fig. 5. A. Kidney section from an EHS immunized rat demonstrating linear TBM staining with linear-granular mesangial deposits and slight linear GBM
deposits. Anti-rat IgG (X 160). B. Kidney section from an EHS immunized rat demonstrating linear deposits of IgG on the TBM and peritubular capillaly
vascular structures. Stained for IgG (X 160).
Discussion
The study of glomerulonephritis in humans depends on appro-
priate animal models for delineation of pathogenetic processes.
Since loss of tolerance and autoimmunity are likely responsible
for most cases of glomerulonephritis in humans, models utilizing
infusion of preformed antibodies, immune complexes or exoge-
nous substances which bind to the kidney are less applicable to the
examination of human autoimmune anti-GBM mediated disease
than models employing endogenous antigens. The most widely
studied model of autoimmune anti-GBM glomerulonephritis was
described in the 1960's by Steblay who immunized sheep with
multiple doses of glomeruli and produced proliferative nephritis
over months which led to proteinuria and uremia [211. Immuni-
zation of most other species using his protocol including dogs,
guinea pigs, rabbits, rats and mice resulted in circulating and
bound antibodies to GBM and proteinuria but not glomerulone-
phritis with decreased renal function [22—25]. The immunofiuo-
rescence and histologic findings in kidney sections of experimental
p p
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Blast transformation — EHS and GBM immunized rats
Fig. 7. Blast transformation of immunized rats to EHS and GBM. Mono-
nuclear cells from EHS immunized rats respond vigorously to mitogenic
stimulation but do not demonstrate any in vitro reactivity to csGBM or
EHS antigen. Animals immunized with csGBM demonstrate antigen
specific response to the immunogen. Dosages are: ConA (4 g/ml);
csBGM (100 xgIml); EHS-AA (100 jrg/ml).
animals and man with glomerulonephritis are similar. Antibodies
eluted from kidneys of nephritic sheep react with basement
membranes of various species and organs [26, 27]. In addition,
sheep antibody inhibits the reaction of Goodpasture antibody with
GBM, and eluates from nephritic sheep recognize M2, the bovine
a1col(IV) chain homologous to the NC1 domain recognized by
Goodpasture serum [28, 291.
Since GBM is rich in col(IV) and can produce experimental
glomerulonephritis, and EHS tumor is an easily accessible source
of abundant col(IV), EHS col(IV) has been used as the immuno-
gen by numerous investigators to attempt to develop experimental
models of glomerulonephritis and to study the epitope(s) respon-
sible for Goodpasture syndrome [30—37]. Serum from patients
with Goodpasture's syndrome is positive against EHS tissue sec-
tions, in ELISA and Western blot against EHS, and activity can be
absorbed with EHS tumor [31]. Furthermore, EHS tumor can
absorb the ability of classic anti-GBM nephrotoxic serum antibody
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Fig. 6. Total urinaty protein (TUP)/24 hours in rats immunized with csEHS
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to induce abnormal urinary protein in rats [32]. These observa-
tions all suggest that EHS col(IV) should contain nephritogenic
antigen(s).
Indeed, numerous publications have described the production
of experimental nephropathies by active EHS immunization or
passive administration of anti-EHS antiserum. Kazama et a!
injected live EHS cells subcutaneously in rats without adjuvant
and produced a nephropathy which was similar to autologous
immune complex nephropathy but accompanied by TBM deposits
[33]. Although subepithelial deposits were present ultrastructur-
ally, there was no proteinuria and no proliferative glomerulone-
phritis. Linear deposits of rat IgG were present on the TBM but
only granular GBM deposits. There was circulating antibody to
brush border TBM antigens. Kawachi et a! immunized rabbits to
produce anti-EHS antibody and passively administered this serum
to rats and mice [32]. Intense staining of the glomeruli occurred
with localization to the mesangium and GBM but no abnormal
proteinuria or glomerulonephritis developed even with preimmu-
nization against rabbit IgG. Wick, MUller and Timpi produced
rabbit anti-EHS tumor and injected mice, causing respiratory
distress but minimal glomerulonephritis [34], The administered
antibody fixed more strongly to the mesangium than to the GBM
although slight staining of the GBM was present. Von der Mark et
al actively immunized mice with EHS resulting in formation of
antibodies which deposited mostly in the mesangium with lesser
amounts on the GBM [35]. They noted the haplotype of the mice
appeared to be involved in the degree of immune response to the
immunogen. Inflammatory changes in the kidney were not noted.
Yaar et a! and Wick et a! actively immunized rabbits to produce
anti-EHS antiserum [36, 37]. Administration of the EHS antibody
resulted in fixation to GBM and TBM in animals and respiratory
distress but no proteinuria and minimal renal histologic abnor-
malities. In addition, actively immunized mice had minimal if any
histologic abnormalities and no proteinuria. Immunofluorescent
examination of glomeruli revealed mesangial staining with mini-
mal GBM and TBM deposits. In none of these models using EHS
antigen was data presented on positive controls demonstrating
that GBM could induce EAG, or indeed that the animal species
was capable of developing glomerulonephritis. The presence of
antibody on the GBM is not necessarily pathogenic, nor does the
additional presence of proteinuria signify the inflammatory pro-
cess of glomerulonephritis, as found in humans [1, 2].
The model which we have described in rats utilizes specific
strains and immunization protocols with the consequent induction
of EAG. Studies by Sado et al suggest that the responsible epitope
is contained on the a3col(IV) chain, the site of the putative
Goodpasture epitope [38]. Indeed Hudson et al, have localized
the majority of antibody reactivity in Goodpasture serum to the
last 36 amino acids of a3co!(IV) [9]. Furthermore, administration
of dimers of a3col(IV) obtained by chromatography can produce
glomerulonephritis in rabbits [39]. In our hands, however, we have
been unable to produce EAG in our rat model using synthetic
peptides containing the Goodpasture epitope [20]. Synthetic
peptide epitopes are not always analogous to native epitopes and
the Goodpasture epitope is clearly cryptic in nature [17, 40].
Therefore, we decided to investigate the hypothesis that native
non-a1, a2 chains were involved in production of glomerulone-
phritis making use of the documented lack of significant quantities
of collagen chains other than a and a2 in EHS tumor.
As shown here, rats immunized with preparations of ERS
basement membrane developed antibodies directed to GBM
which bound to kidney along the TBM and mesangium but only
slightly to the GBM. The antibodies were reactive with constitu-
ents of the GBM and EHS tumor in ELISA and Western blot
analysis, but the immune response was less than animals immu-
nized with an equivalent amount of csGBM. The antibody re-
sponse to EHS-SS and -AA differed from each other to some
extent. This may represent different degrees of purity of true
collagen components achieved by the two preparative methods,
but this is speculation. Nonetheless, while both resulted in an
antibody response, neither caused disease. SDS-PAGE of GBM
and EHS showed absence of novel a3col(IV) monomers and
corresponding dimers in EHS as described by Wisdom et al and
Kleppel et al [13, 14]. In addition, EAG rats had antibody to
bovine M2 and recombinant a3col(IV) while EHS rats lacked a
response to this Goodpasture antigen.
Finally, EHS immunized rats did not mount a cellular response
to EHS or to GBM antigen while positive control EAG rats did.
This suggests that EHS immunization with tumor consisting
mostly or completely of a1 and a2col(IV) chains, while resulting in
a modest antibody response, does not induce as vigorous an
immune response as GBM antigen, that a significant cellular
immune response is not elicited, that the distribution of antibodies
deposited on the basement membrane are different from those
seen in EAG, and that the elicited immune response does not
produce glomerulonephritis or proteinuria. Thus, the formation
of antibody to co!(IV) using a protocol productive of EAG in our
model using GBM does not cause EAG with EHS consisting of a1
and a2col(IV) protein. This suggests that the nephritogenic
antigen was not contained in EHS preparations—as hypothesized.
These findings further suggest that epitope(s) on the same NC1 a3
co!(IV) which contains Goodpasture epitope are necessary to
induce EAG in our model. This information is indirect since we
have not immunized rats with purified a3col(IV). In addition, we
cannot rule out the possibility that other novel chains of GBM
basement membrane are involved in our model since a4 and a5
have also been reported as diminished or absent in EHS com-
pared to GBM [14]. Further studies will be needed with the
a3col(IV) protein or peptides to determine whether the Good-
pasture epitope, which is reportedly responsible for Goodpasture
syndrome in humans, is sufficient and effective in producing EAG
in our model. However, the inability of EHS antigen to induce
EAG in our model provides further evidence of the similarity of
this model in rats to Goodpasture disease in humans.
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